Mirum Pharmaceuticals Inc. (MIRM)
NASDAQ: MIRM · Pharmaceutical Preparations · Foster City, CA
Our rating: Positive
Positive reaffirmed at $96.97, moderate conviction, November 4, 2026.
Breaks if: Revenue growth for the next full fiscal year prints below 25% year-on-year, or free cash flow turns negative for two consecutive reported quarters — either condition signals that the commercial momentum underwriting this multiple has broken down and the Positive call does not hold.
Key figures
| Market value | $6.3B |
|---|---|
| Revenue, last 12 months | $671M |
| Net income, last 12 months | −$904M |
| Free cash flow, last 12 months | −$274M |
| Price to earnings | n/a |
| Free cash flow yield | −4.4% |
| Dividend yield | 0.0% |
| Operating margin | −133.6% |
| Return on equity | −760.0% |
| Beta to the S&P 500 | 0.84 |
| Volatility, annualized | 48.4% |
Reported quarters
| Quarter ending | Revenue | Year on year | Earnings per share | Free cash flow |
|---|---|---|---|---|
| September 30, 2026 | $186M | 39.6% | $-0.87 | −$6M |
| June 30, 2026 | $176M | 37.9% | $-1.06 | −$44M |
| March 31, 2026 | $160M | 43.3% | $-13.43 | −$229M |
| December 31, 2025 | $149M | 49.8% | $-0.12 | $5M |
| September 30, 2025 | $133M | 47.2% | $0.05 | $39M |
| June 30, 2025 | $128M | 64.1% | $-0.12 | $12M |
| March 31, 2025 | $112M | 61.2% | $-0.30 | −$2M |
| December 31, 2024 | $99M | 42.9% | $-0.49 | −$5M |
Three-model forecasts for the next quarter
Written November 21, 2026, before the report. Each settles from the SEC filing.
- Revenue for the quarter is at least $0.21B: Claude 72%, Gemini 70%, Mistral 78%
- Diluted earnings per share are above zero: Claude 22%, Gemini 10%, Mistral 20%
- Free cash flow for the quarter is at least $0.01B: Claude 45%, Gemini 35%, Mistral 30%
16 ledger entries and 25 corporate events on record. Share price as of November 20, 2026. Research and education only. Not investment advice. Stoquity does not manage money or know your circumstances. Ratings, forecasts and lists are produced by software and AI models and can be wrong. Performance figures are hypothetical, measured on paper against a benchmark, and say nothing certain about the future.